The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical outcomes. Recent software innovations enable animal researchers to mirror multi-arm, multi-site, clinical trials with rolling enrollment and run “piggy-backed” studies under a common protocol. Attendees will learn about historical and current methods of preclinical study management and learn about the latest technological innovation, it's possibilities and impact on drug discovery.